白血病诊治中的分子学检测及其临床意义 <sup>*</sup>

doi:10.13523/j.cb.20190913

中国生物工程杂志

2019, Vol. 39

Issue (9): 98-102 DOI: 10.13523/j.cb.20190913

综述

白血病诊治中的分子学检测及其临床意义 ^*

秦亚溱

北京大学人民医院北京大学血液病研究所国家血液系统疾病临床医学研究中心北京 100044

Detection and the Clinical Significance of Molecular Markers in the Diagnosis and Treatment of Leukemia

QIN Ya-zhen

Peking University People’s Hospital, Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease, Beijing 100044, China

全文: PDF(378 KB) HTML

摘要：

精准治疗是当前白血病治疗的新策略,而准确诊断和预后分层是精准治疗的基础。目前白血病主要依据形态学、免疫学、遗传学和分子学进行综合性的诊断分型。近年来,大量白血病相关的分子学异常被确认,分子学检测在白血病诊治中发挥着越来越重要的作用。PCR和测序是临床常规中基本的分子学检测技术。白血病常用的分子学指标包括融合基因、基因突变、基因过表达等,它们在白血病的诊断、靶向治疗的选择、微小残留病的监测以及预后等方面具有重要的临床意义。

关键词： 分子学指标; 白血病; 临床意义

Abstract:

Precision treatment is the present therapeutic strategy to leukemia, and accurate diagnosis and prognostic stratification is the basis. At present, leukemia typing is based on the combination of morphology, immunotyping, cytogenetics and molecular biology. In the past decades, due to the identification of a lot of new molecular abnormalities, molecular detection is becoming more and more important in the diagnosis and treatment of leukemia. The basic techniques for molecular detection are PCR and sequencing. The common leukemia related molecular markers include fusion gene, gene mutation and gene overexpression, and they have shown important clinical significances in the diagnosis, the selection of target therapy, the monitoring of measurable residual disease (MRD) and prognosis.

Key words: Molecular marker Leukemia Clinical significance

收稿日期: 2019-08-22 出版日期: 2019-09-20

ZTFLH:

Q819

基金资助: * 国家自然科学基金(81870125)

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	秦亚溱

引用本文:

秦亚溱. 白血病诊治中的分子学检测及其临床意义 ^*[J]. 中国生物工程杂志, 2019, 39(9): 98-102.

QIN Ya-zhen. Detection and the Clinical Significance of Molecular Markers in the Diagnosis and Treatment of Leukemia. China Biotechnology, 2019, 39(9): 98-102.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20190913 或 https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I9/98

[1]	Baccarani M, Deininger MW, Rosti G , et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013,122(6):872-884. doi: 10.1182/blood-2013-05-501569
[2]	D?hner H, Estey E, Grimwade D , et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017,129(4):424-447.
[3]	Tallman M S, Wang E S, Altman J K , et al. Acute myeloid leukemia, Version 3.2019, NCCN clinical practice guidelines in oncology. Journal of National Comprehensive Cancer Network, 2019,17(6):721-749.
[4]	中华医学会血液学分会实验诊断学组, 中国慢性髓性白血病联盟专家组. 中国慢性髓性白血病诊疗监测规范(2014年版). 中华血液学杂志, 2014,35(8):781-784.
	Chinese Society of Hematology, Chinese Medical Association, Chinese CML Committee . Guideline for the diagnosis and management in the disease monitoring of patients with chronic myeloid leukemia in China (2014). Chinese Journal of Hematology, 2014,35(8):781-784.
[5]	中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版). 中华血液学杂志, 2017,38(3):177-182.
	Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association . Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL)(2017). Chinese Journal of Hematologyi, 2017,38(3):177-182.
[6]	秦亚溱, 黄晓军 . 新一代检测技术在白血病精准医疗中的应用及挑战. 中华血液学杂志, 2019,40(5):353-357.
	Qin Y Z, Huang X J . Application and challenges of the new generation detection technologies in precision medicine for leukemia, Chinese Journal of Hematology, 2019,40(5):353-357.
[7]	Thiede C, Koch S, Creutzig E , et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 2006,107(10):4011-4020.
[8]	Hoffbrand A V, Higgs D R, Keeling D M , et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press, 2008: 110-123.
[9]	Arber D A, Orazi A, Hasserjian R , et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016,127(20):2391-2405.
[10]	Bj?rkholm M, Ohm L, Eloranta S , et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol, 2011,29(18):2514-2520. doi: 10.1200/JCO.2011.34.7146
[11]	Saussele S, Richter J, Guilhot J , et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol, 2018,19(6):747-757.
[12]	Soverini S, Hochhaus A, Nicolini F E , et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 2011,118(5):1208-1215. doi: 10.1182/blood-2010-12-326405
[13]	Winer E S, Stone R M . Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol, 2019, Doi: 10.1177/2040620719860645. doi: 10.1177/2040620719860645
[14]	秦亚溱, 李金兰, 主鸿鹄 , 等. 实时定量R T-PC R技术测定初治白血病患者常见融合基因转录子水平及其标准化的探讨. 中华血液学杂志, 2007,28(7):353-357.
	Qin Y Z, Li J L, Zhu H H , et al. Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique. Chinese Journal of Hematology, 2007,28(7):353-357.
[15]	Hughes T, Deininger M, Hochhaus A , et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006,108(1):28-37.
[16]	秦亚溱, 马道新, 王云贵 , 等. 转换国际标准化的 BCR-ABL(P210)转录本水平的转换系数多中心再确认研究. 中华血液学杂志, 2015,36(10):814-817.
	Qin Y Z, Ma D X, Wang Y G , et al. A multicenter study on the revalidation of validated conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia. Chinese Journal of Hematology, 2015,36(10):814-817.
[17]	Alvarnas J C, Brown P A, Aoun P , et al. Acute lymphoblastic leukemia,Version 2. 2015: clinical practice guidelines in oncology. Journal of The National Comprehensive Cancer Network, 2015,13(10):1240-1279.
[18]	Yin J A , O’Brien M A, Hills R K , et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood, 2012,120(14):2826-2835. doi: 10.1182/blood-2012-06-435669
[19]	Zhu H H, Zhang X H, Qin Y Z , et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood, 2013,121(20):4056-4062. doi: 10.1182/blood-2012-11-468348
[20]	Qin Y Z, Wang Y, Xu L P , et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol, 2017,10(1):44.

[1]	陶守松,任广明,尹荣华,杨晓明,马文兵,葛志强. 敲低去泛素化酶USP13抑制K562细胞的增殖^*[J]. 中国生物工程杂志, 2021, 41(5): 1-7.
[2]	王谦,陈苏宁. 混合表型急性白血病的细胞及分子遗传学研究进展[J]. 中国生物工程杂志, 2019, 39(9): 91-97.
[3]	贺玲玲,骆婷婷,常艳,王亚哲,袁晓英,石韦华,赖悦云,石红霞,秦亚溱,黄晓军,刘艳荣. 28例急性巨核细胞白血病实验室检查结果分析 ^*[J]. 中国生物工程杂志, 2019, 39(9): 2-10.
[4]	刀凤亭,杨璐,王亚哲,常艳,袁晓英,李玲娣,陈文敏,龙玲玉,刘艳荣,秦亚溱. 成人t(8;21)急性髓系白血病患者初诊Ki-67的表达特征及预后意义 ^*[J]. 中国生物工程杂志, 2019, 39(9): 11-18.
[5]	赵四书,刘露,刘芳,仇海荣,范磊,李建勇,吴雨洁. CD11c在慢性淋巴细胞白血病诊断中的意义 ^*[J]. 中国生物工程杂志, 2019, 39(9): 19-24.
[6]	张暕,姜志平,徐萍,何群,王清,朱艳,赵谢兰. 伊马替尼血药浓度监测指导慢性粒细胞白血病患者的研究[J]. 中国生物工程杂志, 2019, 39(9): 25-32.
[7]	陈曼,王爱先,傅旻婧,吴雪英,甄军毅,宫美维,郭亚,王卉. CAR细胞疗法在T细胞-急性淋巴细胞白血病应用的新进展[J]. 中国生物工程杂志, 2019, 39(9): 103-107.
[8]	汪路,杨丽媛,唐雨婷,陶瑶,雷力,敬一佩,蒋雪坷,张伶. 干扰PKM2对人白血病细胞增殖和凋亡的影响及潜在机制 ^*[J]. 中国生物工程杂志, 2019, 39(3): 13-20.
[9]	张鹤铭, 蔡楚凡, 刘杨, 甘龙站, 焦雪苗, 田永强. 人白血病抑制因子在原核细胞中的表达与纯化[J]. 中国生物工程杂志, 2017, 37(9): 7-14.
[10]	曾杰. 优质L-天冬酰胺酶的开发与应用及重组表达研究进展[J]. 中国生物工程杂志, 2017, 37(11): 123-131.
[11]	黄晨, 王家融, 杨吉成, 盛伟华, 缪竞诚. Ad.RGD-ING4-PTEN对MEG01人白血病细胞的抑制作用[J]. 中国生物工程杂志, 2014, 34(3): 9-17.
[12]	张砚君, 刘荣, 张梦楠, 苗庆芳, 甄永苏, 熊冬生, 张益芝. IL3融合蛋白稳定性分析、改造及活性研究[J]. 中国生物工程杂志, 2013, 33(3): 117-122.
[13]	邵会媛, 苗宗玉, 覃凤娴, 陈先春, 谭诗, 钟梁, 张伶. NPM1突变基因表达抑制K562白血病细胞体外增殖和侵袭[J]. 中国生物工程杂志, 2010, 30(11): 6-10.
[14]	李平法刘辉詹合琴. 组蛋白乙酰转移酶PCAF通过与PML蛋白的作用而定位于细胞核ND10结构[J]. 中国生物工程杂志, 2010, 30(06): 21-27.
[15]	杨琳,罗建民,刘小军,成志勇,温树鹏,杜行严,杨晓阳,武学文. SHIP基因真核表达载体的构建、鉴定及其表达抑制白血病细胞增殖的实验研究[J]. 中国生物工程杂志, 2009, 29(06): 14-19.

Viewed

Full text

Abstract

Cited

Shared

Discussed